Phathom Pharmaceuticals I... (PHAT)
6.90
0.11 (1.62%)
At close: Jan 15, 2025, 10:04 AM
Company Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 452 |
| CEO | Terrie J. Curran |
Contact Details
Address: 100 Campus Drive Florham Park, New Jersey United States | |
| Website | https://www.phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Terrie J. Curran | President, Chief Executive Officer & Director |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & Chief Operating Officer |
| Paul Cocja | Chief People Officer |
| David A. Socks | Co-Founder & Director |
| Dr. Aditya Kohli Ph.D. | Co-Founder |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer |
| Martin J. Gilligan | Chief Commercial Officer |
| Molly Henderson CPA, MBA | Chief Financial & Business Officer |
| Tom Harris | Chief Development Sciences Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 4 | Filing |
| Dec 20, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 11, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 05, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 05, 2024 | SCHEDULE 13G | Filing |